Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
4.090
+0.170 (4.34%)
May 18, 2026, 4:00 PM EDT - Market closed
Evaxion Revenue
Evaxion had revenue of $7.53M in the twelve months ending March 31, 2026, up 128.61% year-over-year. In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth.
Revenue (ttm)
$7.53M
Revenue Growth
+128.61%
P/S Ratio
4.53
Revenue / Employee
$163,652
Employees
46
Market Cap
34.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.53M | 4.18M | 125.12% |
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Apollomics | 8.84M |
| CervoMed | 2.09M |
| Daré Bioscience | 1.16M |
| Pluri | 1.08M |
| Senti Biosciences Holdings | 38.00K |
EVAX News
- 6 days ago - Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress - GlobeNewsWire
- 11 days ago - Evaxion Earnings Call Transcript: Q1 2026 - Transcripts
- 11 days ago - Evaxion announces business update and first quarter 2026 financial results - GlobeNewsWire
- 14 days ago - Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 - GlobeNewsWire
- 21 days ago - Evaxion Biotech management to meet with Maxim - TheFly
- 21 days ago - Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer - GlobeNewsWire
- 4 weeks ago - Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial - TheFly
- 4 weeks ago - Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial - GlobeNewsWire